FDA
-
-
-
-
-
-
-
BMS-986446 receives FDA fast track designation for alzheimer's treatment
-
-
-
-
-
-
-
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights
-
-
-
-
-
-
-
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
-
-
-
-
-
-
-
Prothena Reports Second Quarter 2023 Financial Results and Business Highlights
-
-
-
-
-
-
-
Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights
-
-
-
-
-
-
-
Prothena Reports First Quarter 2022 Financial Results and Business Highlights
-
-
-
-
-
-
-
Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights
-
327,801 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

